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Abstract 
About 80% of the population worldwide use a variety of traditional medicine, including herbal medicines, for the diagnosis, prevention 
and treatment of illnesses, and for the improvement of general well-being. Total consumer spending on herbal dietary supplements in 
the United States reached an estimated $8.085 billion in 2017. In addition, the 8.5% increase in total sales from 2016 is the strongest 
growth for these products in more than 15 years. The main reason to use herbal products in these countries is the assumption of a 
better tolerability compared to synthetic drugs. Whereas in developing countries herbal medicines are mostly the only available and   
affordable treatment option. Surveys from industrialized countries reveal as main health areas in which herbal products are used for 
upper airway diseases including cough and common cold; other leading causes are gastrointestinal, nervous and urinary complaints 
up to painful conditions such as rheumatic diseases, joint pain and stiffness. Gastrointestinal disorders are the most widespread 
problems in health care. Many factors may upset the GI tract and its motility (or ability to keep moving), including: eating a diet low in 
fiber; lack of motion or sedentary lifestyle; frequent traveling or changes in daily routine; having excessive dairy products; anxiety and 
depression; resisting the urge to have a bowel movement habitually or due to pain of hemorrhoids; misuse of laxatives (stool softeners) 
that, over time, weaken the bowel muscles; calcium or aluminum antacids, antidepressants, iron pills, narcotics; pregnancy. About 30% 
to 40% of adults claim to have frequent indigestion, and over 50 million visits are made annually to ambulatory care facilities for 
symptoms related to the digestive system. Over ten million endoscopies and surgical procedures involving the GI tract are performed 
each year. Community-based studies from around the world demonstrate that 10% to 46% of all children meet the criteria for RAP. 
Gastrointestinal disorders such as chronic or acute diarrhea, malabsorption, abdominal pain, and inflammatory bowel diseases can 
indicate immune deficiency, present in 5% to 50% of patients with primary immunodeficiencies. The gastrointestinal tract is the largest 
lymphoid organ in the body, so it is not surprising that intestinal diseases are common among immunodeficient patients. 
Gastroenterologists therefore must be able to diagnose and treat patients with primary immunodeficiency. Further, pathogens do 
influence the gut function. On the other hand, dietary habits and specific food types can play a significant role in the onset, treatment, 
and prevention of many GI disorders. Many of these can be prevented or minimized by maintaining a healthy lifestyle, and practicing 
good bowel habits.  
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Purpose of The Study: Review of proper utilization foods, herbs 
and other alternative treatment options to prevent minor GI 
disorders. 
 
Methodology: Comprehensive literature search followed by 
consulting healthcare professionals about GI disorders. 
Hospital, clinic and company personnel, newspaper journalists, 
NGO workers and a few folk healers, alternative medicine 
specialists given their valuable suggestions. A few western 
magazine and newspapers also observed to get the necessary 
concern. The present study was started from the beginning of 
2018. PubMed, ALTAVISTA, Embase, Scopus, Web of Science, 
and the Cochrane Central Register of was thoroughly searched. 
The keywords were used to search for different publishers’ 
journals like Elsevier, Springer, Willey Online  
Library, Wolters Kluwer were extensively followed.  
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Projections were based on public life pattern, their food habits, 
contamination sources, different uses of available herbs and 
daily-consumed foods, their medicinal values in minor GI 
ailments. 
 
Findings: Conventional treatments unable to prove themselves 
in GI disorders more often. Complimentary drugs, probiotics 
along with food and lifestyle adjustment according to suggested 
guideline ensures patient satisfaction, improves HRQoL, reduce 
exacerbation. Further research necessary to both system of 
medicine to be more trustworthy and to ensure more fruitful 
outcome in this arena. 
 
Limitation of the study: Lack of recent statistical research data 
found in this arena of study, however, data obtained from valid 
sources are added to this article.   
 
Practical Implication: Along with pharmacists, pharmacy 
students, physicians, nurses and other health workers, policy 
makers, conscious general people have to assimilate many 
subject matters from this article. 
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Article Highlights:  
1. About 80% of the population worldwide use a variety 
of traditional medicine. 
2. Sales of HDS in US passed $8 billion in 2017, with 8.5% 
increase in total sales from 2016. 
3. In community settings, almost 50% of patients with 
FGIDs used CAM therapies 
4. GERD affects up to 40% of the population, 40%-50% 
of patients with GERD have abnormal peristalsis. 
5. 20–30% continue to experience reflux symptoms 
despite PPI treatment 
6. Dyspepsia affects 20% of the global population, 30–
70% of the patients with functional dyspepsia 
experience delayed gastric emptying. 
7. Dyspepsia prevalence was 30.4% in India, 24% in 
Spain and 45% in Nigeria.  
8. The prevalence of functional dyspepsia is 12-15% in 
patients with IBS. 
9. 30% of the general population experiences 
constipation during lifetime but incidence sometimes 
rises up to 80% in critically ill patients. 
10. The economic burden of IBS in the U.S. is estimated at 
$28 billion annually, 32% of IBS-C patients suffer 
depression as their condition almost every day in the 
previous month. 
11. Sexual dysfunction is positively associated with 
perceived GI symptom severity and HRQoL 
 
 
Figure 1. Graphical Abstract 
 
Introduction 
The digestive system is dedicated to breaking down food and 
allowing its nutrients to be absorbed into the bloodstream, 
from where they are then carried to every part of the body. 
Spices and herbal remedies have been used since ancient times 
to treat a variety of disorders. It has been experimentally 
demonstrated that spices, herbs, and their extracts possess 
antimicrobial, anti-inflammatory, antirheumatic, lipid-
lowering, hepatoprotective, nephroprotective, antimutagenic 
and anticancer activities, besides their gastroprotective and 
anti-ulcer activities. Nowadays, several experimental studies 
and, to a lesser extent, clinical trials have also emphasized the 
role of herbs in the treatment of a variety of disorders. Several 
herbs and herbal extracts have been shown to possess 
antibacterial properties. For instance, onion, garlic, ginger, 
pepper and mustard have demonstrated antimicrobial activity 
against several types of bacteria. Tayel and El-Tras have 
recently reported a potent antibacterial activity of cinnamon 
and clove against several bacterial strains. Some spices possess 
antifungal activity. Beside their antifungal activity, herbs have 
also shown vermicidal, nematocidal and molluscicidal potential. 
In addition, gingerol, the active ingredient of ginger, and 
eugenol have shown anti-inflammatory and antirheumatic 
activity. More recent studies have also demonstrated anti-
inflammatory and antirheumatic properties of herbs. 
Furthermore, gingerol and curcumin have also shown lipid-
lowering potential in experimental animals as well as in clinical 
trials. The mechanism of epigastric pain and dyspepsia induced 
by red and black pepper is not well-defined. However, it is 
believed to be a consequence of inhibition of gastric surface 
hydrophobicity, enhancement of surface wettability and 
activation of intramucosal pain receptors. Some spices may 
stimulate acid secretion and have deleterious effects on the 
gastric mucosal lining. Intragastric perfusion of albino rats with 
aqueous extracts of red pepper, fennel, omum/ajwain, 
cardamom, black pepper, cumin and coriander have stimulated 
a cholinergic response, and/or via other mechanism(s) have 
induced acid secretion with a respectively. 
 
GERD  
The AGC guidelines define GERD as “symptoms or complications 
resulting from the reflux of gastric contents into the esophagus 
or beyond, into the oral cavity (including larynx) or lung. GERD 
is one of the most common diseases in society, affecting up to 
40% of the population [22]. A systematic review demonstrated 
that the prevalence of GERD ranged from 18.1% to 27.8% in 
North America, 8.8% to 25.9% in Europe, 2.5% to 7.8% in East 
Asia, 8.7% to 33.1% in the Middle East, 11.6% in Australia, and 
23.0% in South America [1]. The cardinal symptoms of GERD are 
heartburn and regurgitation. However, GERD may present with 
a variety of other symptoms, including water brash, chest pain 
or discomfort, dysphagia, belching, epigastric pain, nausea, and 
bloating. In addition, patients may experience extraesophageal 
symptoms like cough, hoarseness, throat clearing, throat pain 
or burning, wheezing, and sleep disturbances [2]. 
Approximately 50% of the patients presenting with heartburn 
have erosive esophagitis on upper endoscopy, up to 70% of 
these patients have normal endoscopy findings. Furthermore, 
40% of those with normal endoscopy findings and normal pH 
test results have reflux hypersensitivity (a positive correlation 
between symptoms and reflux events), and 60% have functional 
heartburn [8]. Impaired aspects of quality of life are disturbed 
sleep, reduced vitality, generalized body pain, unsatisfactory 
sex life, and anxiety. Nocturnal symptoms caused by reflux 
appear to have a particularly marked influence on quality of life 
and the burden of illness imposed by GERD also has an impact 
on work productivity [23]. Studies have demonstrated that 
symptom frequency, severity, or combination of both are not 
predictive of any specific phenotypic presentation of GERD [3]. 
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However, elderly patients with GERD appear to experience a 
more severe mucosal disease that is associated with overall 
milder and more atypical symptoms [4]. 40%-50% of patients 
with GERD have abnormal peristalsis. This dysmotility is 
particularly severe in about 20% of patients because of very low 
amplitude of peristalsis and/or abnormal propagation of the 
peristaltic waves (ineffective esophageal motility) 17]. Other 
symptoms of GERD include: sore throat; sour taste in the back 
of the mouth; asthma symptoms (prevalence of GERD found in 
30% to 65% patients with asthma), dry cough; trouble 
swallowing [18,19]. Psychological comorbidity (anxiety, 
hypervigilance, depression, and somatization) does play an 
important role in patients with refractory heartburn [7]. GERD 
has emerged as a comorbidity of asthma and COPD. The 
prevalence of GERD in asthma patients has ranged from 25% to 
80%, 38% of asthma patients had GERD in another study [1], 
[44]. The prevalence of GERD in COPD ranges from 17% to 78%. 
Although GERD is usually confined to the lower esophagus in 
some individuals, it may be associated with pulmonary micro-
aspiration of gastric contents [45]. The overall prevalence of IBS 
symptoms in the GERD population ranges from 10-74% [64]. 
 
Lifestyle Modification for Gastroesophageal Reflux 
Mediterranean (frequent consumption of composite and/or 
traditional dishes, fresh fruit and vegetables, olive oil, and fish) 
to a beneficial effect in the occurrence of GERD [24]. Patients 
with reflux often benefit from a diet that avoids specific food 
triggers. In particular, fatty foods, spicy foods, acidic foods, 
chocolate, and caffeine worsen reflux symptoms. Prior to 
completely eliminating wheat, a celiac screen should be 
performed with a tissue transglutaminase IgA antibody, and a 
total IgA level [21]. Even modest weight gain can exacerbate 
GERD symptoms and women who reduced their BMI by 3.5 
units or more reported a 40% reduction in the frequency of 
GERD symptoms compared with controls [5]. Cessation of 
tobacco, alcohol, chocolate, caffeine or coffee, citrus, mint or 
spicy food may improve in clinical or physiological parameters 
of GERD [6]. Chewing gum stimulates the production of saliva, 
it helps dilute and clear the acid from unwanted areas [26]. 
 
Exhibit 1. Non-Drug Treatment Options of GERD [10], [20], [30] 
1.  Elevation of the bed head (15 cm) 
2.  Moderation in the ingestion of the following foods (based on symptom correlation): fatty foods, citrus, coffee, alcoholic and/or carbonated beverages, mint, peppermint, tomato, chocolate 
3.  Refraining from wearing tight-fitting clothes: Clothes that are tight around the waist can put extra pressure on your stomach. This added pressure can then affect the LES, increasing reflux. 
4.  Avoidance of lying down in the 2 h following meals. Lying down too soon after meals can induce heartburn.  
5.  Eliminate distractions at mealtime. Avoid reading, checking phone, or watching television while eating.  Chew each bite thoroughly. Eat smaller meals rather than big meals. Overeating puts more pressure on lower esophageal sphincter. 
6.  Quitting of smoking 
7.  Reduction of body weight, if overweight 
 
GERD Expenditure 
GERD is a common, chronic, relapsing symptom. Often people 
self-diagnose and self-treat it even though health-related 
quality of life is significantly impaired. In the lack of a valid 
alternative approach, current treatments focus on suppression 
of gastric acid secretion by the use of PPIs, but people with 
GERD have a significantly lower response rate to therapy [9], 
approximately 20–30% continue to experience reflux 
symptoms despite PPI treatment [11]. 30–40% of patients 
receiving medical therapy with PPIs experience troublesome 
breakthrough symptoms, and recent evidence suggests that 
this therapy is related to increased risk of complications [12]. In 
the US alone, overall spending on all GI diseases is estimated to 
be $142 billion (in 2009 US dollars) per year in direct and 
indirect costs. GERD accounts for approximately $15–20 billion 
of these direct and indirect costs. It has been estimated that 
prescribed medications for GERD, primarily PPIs, account for 
over 50% of prescriptions for all digestive diseases, resulting in 
around $10 billion in annual direct health care costs [25,26]. 
Extraesophageal manifestations of reflux, including LPR, 
asthma, and chronic cough, have been estimated to cost $5438 
per patient in direct medical expenses in the first year after 
presentation and $13,700 for 5 years [28]. 
 
Herbs for GERD Management 
Some research has also shown improved symptoms in people 
with GERD who take peppermint oil.  Historically, ginger has 
been used to treat other gastrointestinal ailments, including 
heartburn. This may reduce overall swelling and irritation in the 
esophagus. Caraway, garden angelica, German chamomile 
flower, greater celandine, licorice root, lemon balm, milk thistle 
and turmeric have little clinical evidence to support their 
effectiveness [29]. Fermented foods, like kimchi (alkaline), can 
be incredibly helpful for digestive system. Consuming a 
spoonful of mustard during the onset of acid reflux symptoms 
of heartburn by balancing pH levels. Many patients have seen 
significant benefits from snacking tasty nuts (especially 
almond), to be consumed raw, organic and salt-free. Both 
bananas and apples contain natural antacids that can help 
relieve or prevent an onset of acid reflux [26]. Marshmallow 
(Althea officinalis L.) contains a mucilage quality (may interfere 
with the absorption of other medications) which helps to coat 
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the esophagus and stomach lining, creating a protective barrier 
against stomach acid. It’s an effective stimulator of cell 
physiology of epithelial cells which can prove the traditional use 
of Marshmallow preparations for treatment of irritated mucous 
membranes within tissue regeneration [31,32]. Chewing DGL 
(deglycyrrhizinated licorice) also helps boost enzyme 
production, allowing for easier and quicker digestion as well as 
better absorption of nutrients [32]. Use of low doses of pure 
glycyrrhetinic acid and bilberry anthocyanosides, together with 
alginic acid as addon therapy, substantially improves symptoms 
in patients with nonerosive reflux disease without increasing 
side effects or worsening tolerability or compliance [33]. To add 
to all that nutrition, papaya is an excellent treatment for acid 
reflux. It contains a proteolytic enzyme that breaks down 
proteins in the digestive system into amino acids. The active 
ingredient, papaine, is helpful to the digestion of fats and carbs. 
It aids in digestion and allows body to make acid. The potassium 
in papaya (Carica papaya L.) also introduces healthy bacteria 
into intestines. This can prevent stomach from working as hard 
and helps to stop indigestion and reflux. Papaya is used as a 
natural remedy in abnormal digestion in tropical and 
industrialized countries [34-36]. The fenugreek fiber effects 
were generally similar to the results produced by an OTC 
antacid medication (ranitidine at 75 mg, twice a day). 2 weeks 
intake of a fenugreek fiber product, taken 30 min before two 
meals/day, diminished heartburn severity [37]. The 
cytoprotective effect of the seeds seemed to be not only due to 
the anti-secretory action but also to the effects on mucosal 
glycoproteins. The fenugreek seeds also prevented the rise in 
lipid peroxidation induced by ethanol presumably by enhancing 
antioxidant potential of the gastric mucosa thereby lowering 
mucosal injury. Histological studies revealed that the soluble 
gel fraction derived from the seeds was more effective than 
omeprazole in preventing lesion formation [38]. An 
involvement of Opuntia ficus-indica mucilages (mainly 
cultivated in the Mediterranean region and in Central America) 
has been hypothesized, mainly formed by arabinogalactan and 
galacturonic acid, forming a defense layer in these 
gastroprotective effects. The mucilage is strongly viscous which 
because of the negative charges causes strong intermolecular 
repulsion, resulting in expansion of the molecules. It is believed 
that this changing in molecular shape could be responsible for 
the protection of the gastric mucosa [13-15]. Olive leaf extract 
possesses antioxidant properties, which can positively 
influence gastroprotection. The main iridoide monoterpene 
oleuropein contained in olive leaf was usually thought to be 
responsible for pharmacological effects but it was recently 
observed that olive leaf is as a stable source of bioactive 
flavonoids. In fact, the contribution of flavonoids to the overall 
radical scavenging activity of olive leaf extracts has been 
investigated and luteolin 7-O-glucoside was found to be one of 
the dominant scavengers (8–25%) [16]. Turmeric (Curcuma 
longa) and its compounds (especially Curcumin) should be 
considered as a promising alternative for patients who suffer 
from digestive disorders because it is safe, inexpensive, and 
ubiquitously available. Curcumin has been defined as the most 
active component in C. longa and has considerable 
gastroprotective and antiulcerogenic effect. Improvement in 
clinical scores of GERD and GERD Activity Index is proven with 
turmeric [39,40]. German chamomile (Matricaria recutita) 
(contains flavonoids, in particular apigeningastric shown 
protective effect in clinical trial) and bismuth have known 
gastric protective properties, and Atropa belladonna contains 
anticholinergic agents that have bronchodilatory effect. 
Complementary treatments containing these ingredients could 
be used to treat patient with asthma patients having GERD, and 
if effective, could be an additional treatment tool that could 
also reduce the use of long-term inhaled corticosteroids and 
proton pump inhibitor treatment and thus their side effects 
[41]. Although a number of toxic effects have been attributed 
to bismuth compounds in humans: nephropathy, 
encephalopathy, osteoarthropathy, gingivitis, stomatitis and 
colitis. Whether hepatitis is a side effect, however, is open to 
dispute [42]. Aloe Vera was safe and well tolerated and reduced 
the frequencies of all the assessed GERD symptoms, but 
nephrotoxicity and hepatotoxicity (also human carcinogen, 
Group 2B) is keeping its use in a controversial position [46-49].  
 
Dyspepsia 
Dyspepsia is common, affecting approximately 20% of the 
global population, and is frequently encountered in primary 
care. Functional dyspepsia (FD) is one of the most prevalent 
gastrointestinal disorders, and is defined as a chronic disease 
with persistent upper gastrointestinal symptoms without any 
explanatory organic or metabolic causes [50]. Dyspepsia is a 
very common GI complaint, with up to one in five individuals 
affected worldwide. Of those with dyspepsia, around 40% will 
seek the advice of their primary care physician. Almost 15% of 
patients with dyspepsia are referred to secondary care for 
further investigation and management [58]. When broadly 
defined, dyspepsia occurs in 40%, leads to GP consultation in 
5% and referral for endoscopy in 1% of the population annually. 
In patients with signs or symptoms severe enough to merit 
endoscopy, 40% have functional or non-ulcer dyspepsia, 40% 
have GERD and 13% have some form of ulcer [62]. Heartburn 
and acid regurgitation are no longer considered to be 
symptoms of dyspepsia, but of GER. Both the underlying causes 
and progress of functional dyspepsia are still unknown. That is 
largely true of GERD as well [65]. One-third of patients who visit 
general physician practices are patients with dyspepsia 
syndrome; and half of patients who visit gastroenterologists are 
also patients with dyspepsia syndrome [66]. The prevalence of 
functional dyspepsia was UK (21%), US (26%), Jordan (60%), 
western Iran (18%), China (18.4%) found in a 2014 study [51]. 
In a German study, around one third of the normal persons 
interviewed reported dyspeptic symptoms, including acute 
dyspepsia in 6.5% and chronic dyspepsia in 22.5% of cases [52]. 
8%-30% and 8%-23% of Asian people suffer from of 
uninvestigated dyspepsia and FD, respectively [53]. Dyspepsia 
prevalence was 30.4% in India, 5% in Scandinavian countries, 
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24% in Spain and 45% in Nigeria estimated [68]. Smoking might 
affect all gastrointestinal functions including those of the 
esophagus, stomach, and colon, resulting in susceptibility to 
several kinds of FGIDs including GERD, FD, and IBS [54]. 
Potential lifestyle factors associated with dyspepsia include 
tobacco, alcohol, and analgesic consumption. Furthermore, 
dietary habits that include consumption of smoked food, fast 
food, salty food, coffee/tea, and spicy food were associated 
with aggravating the symptoms of dyspepsia; while fruits, 
vegetables, and water were noted to improve the symptoms 
[68]. FD is more prevalent in women (24.4%) than men (16.6%) 
and its occurrence was found to increase significantly with age 
[69, 70]. Typical dyspeptic symptoms include postprandial 
fullness, early satiety, epigastric pain, and epigastric burning 
[55]. Visceral hypersensitivity, impaired gastric accommodation 
and impaired gastric emptying are commonly reported by 
patients with functional dyspepsia. Involvement of duodenal 
hypersensitivity to the luminal contents, small bowel 
dysmotility, psychological disturbances, central nervous system 
disorders and Helicobacter pylori infection also been reported 
[56]. Delayed gastric emptying has been reported by gastric 
scintigraphy in a large proportion (up to 45%) of dyspeptic 
patients, especially those with PDS [57]. About 30–70% of the 
patients with functional dyspepsia experience delayed gastric 
emptying [86]. The overall costs to the health service associated 
with managing dyspepsia are considerable, estimated to be 
over $18 billion per annum in the United States. Moreover, 
when one considers that dyspepsia impacts on physical, 
mental, and social aspects of health-related quality of life, the 
true overall costs to society are likely to be far higher, and also 
encompass loss of economic productivity due to sickness-
related absence from work [58-60]. The risk of malignancy 
predominantly relates to increasing age, and so guidelines have 
previously recommended upper GI endoscopy to routinely 
investigate dyspepsia only when patients are aged 55 years and 
older [61]. The prevalence of functional dyspepsia (after normal 
upper endoscopy) is 12-15% in patients with IBS [64]. 
 
Exhibit 2. Alarm features in patients with dyspepsia [61] 
 Age > 55 years with new onset dyspepsia* 
 Evidence of overt gastrointestinal bleeding including melaena or haematemesis 
 Dysphagia, particularly if progressive, and odynophagia 
 Persistent vomiting 
 Unintentional weight loss 
 Palpable abdominal or epigastric mass or abnormal adenopathy 
 Family history of upper gastrointestinal cancer 
 Evidence of iron deficiency anemia after blood testing 
* ACG/CAG guidelines now recommend an age threshold of 60 years or older. 
 
 
 
 
 
 
 
Figure 2. Diagnostic algorithm of Helicobacter pylori-associated dyspepsia. 
Patients with dyspeptic symptoms after negative routine laboratory and 
upper gastrointestinal endoscopy except for positive H. pylori tests, should 
undergo eradication therapy. If sustained symptomatic relief is obtained, 
their dyspeptic symptoms are considered as H. pylori-associated 
dyspepsia. On the other hand, if dyspeptic symptoms do not resolve or 
recur after eradication therapy, they are judged to have functional 
dyspepsia. EGD, oesophagastroduodenoscopy (Source: Sugano K, Tack J, 
Kuipers EJ on behalf of faculty members of Kyoto Global Consensus 
Conference, et al Kyoto global consensus report on Helicobacter pylori 
gastritis Gut 2015;64:1353-1367). 
                                                Figure 2 
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Rationale of Alternative Treatments with Dyspepsia 
Prokinetics are recommended for the treatment of functional 
dyspepsia (FD) but systematic reviews give conflicting results on 
the efficacy of these agents [62]. Although several PPI-related 
adverse effects have been reported, their clinical relevance is 
not yet clear. Again, their beneficial effects for functional 
dyspepsia have not been fully confirmed [63]. The popularity of 
CAM in treating FGIDs has steadily increased in Western 
countries. In community settings, almost 50% of patients with 
FGIDs used CAM therapies. Herbal remedies consist of multi-
component preparations, whose mechanisms of action have 
not been systematically clarified. Few studies analyzed the 
effectiveness of acupuncture in Western countries, yielding 
conflicting results and possibly reflecting a population bias of 
this treatment. Hypnosis has been extensively used in irritable 
bowel syndrome, but few data support its role in treating FD 
[67]. 
 
Exhibit 3. Adverse Events Reported in Patients Treated with Proton Pump Inhibitors [63], [84] 
Adverse events unrelated to acid inhibition Adverse events related to acid inhibition 
Allergic reaction to drug chemicals Pneumonia 
Collagenous colitis Gastrointestinal infection 
Acute interstitial nephritis Gastric carcinoid tumor 
Chronic kidney disease Gastric fundic mucosal hypertrophy 
Drug interaction Changes in gut microbiome 
Dementia Small intestinal bacterial overgrowth 
Cerebral ischemic diseases Iron deficiency 
Ischemic cardiac diseases Bone fracture; decrease calcium absorption; Vitamin B12 deficiency; 
Hypomagnesemia; Gastric fundic gland polyps; Gastric & Colon cancer; 
Spontaneous bacterial peritonitis; Hepatic encephalopathy; Drug interaction 
 
Herbs and Probiotics for Dyspepsia 
Flavonoid rich phytochemical composition of the root extract of 
Glycyrrhiza glabra, revealed significant decrease in symptoms 
scores of dyspepsia [71]. Adjuvant supplementation of honey-
based formulation of Black Seed/ black caraway (Nigella sativa) 
can cause significant symptomatic improvement of patients 
with functional dyspepsia whom received the standard anti-
secretory therapy [72]. Basil Leaf (Ocimum basilicum L) 
strengthens stomach, nervous system and is also carminative, 
also has been demonstrated to decrease acid and pepsin 
outputs, widely used as a spice and a typical ingredient of the 
healthy Mediterranean diet [73,74]. The fruit of Amla 
(Phyllanthus emblica L.) has cytoprotective acid-reducing 
features, prevents indigestion, and controls acidity and well 
tolerated [75-77]. Pistacia lenticus Desf. (Mastaki) act against 
different microorganisms (Mustic gum) specially Helicobacter 
pylori, positively affect liver function, could be effective as an 
alternative regime in patients unwilling to undergo eradication 
with the triple therapy regime [78,79]. Rhizome of Ginger 
(Zingiber officinale Roscoe) is stomach tonic, protective, 
antiulcer and is effective for digestion problems, bloating, and 
nausea, stimulated gastric emptying and antral contractions in 
patients with functional dyspepsia [80-83]. Iberogast 
(commercial preparation of 9 herbal extracts including bitter 
candy tuft, lemon balm leaf, chamomile flower, caraway fruit, 
licorice root, angelica root, milk thistle fruit, peppermint leaf, 
and greater celandine herb) has been shown to protect against 
the development of ulcers with decreased acid production, 
increased mucin production, an increase in prostaglandin E2 
release, both safe and effective for treatment of functional 
dyspepsia and IBS in Children [21]. Licorice root, the dried 
rhizome or extracts of glycyrrhiza glabra, has long been used in 
botanical medicine for treatment of gastric inflammation, 
showed a significant decrease in total symptom scores (p < 
0.05) and improvement in quality of life with functional 
dyspepsia [77]. Red pepper as a drug is given in atonic dyspepsia 
and flatulence due to increasing the motility in the gastric 
antrum, duodenum, proximal jejunum and colon. It can also 
increase parietal, pepsin, and bile acid secretions. Chilies are 
known to protect against gastrointestinal ailments including 
dyspepsia, loss of appetite, gastroesophageal reflux disease and 
gastric ulcer due to the several mechanisms such as reducing 
the food transition time through the gastrointestinal tract and 
anti-Helico pylori effects [85]. Celery (Apiumgraveolens), radish 
(Raphinussativus L.), rocket (Eruka sativa), and marjoram 
(Origanummajorana L.) demonstrated anti-ulcer effect in 
experimental investigations [86]. Probiotics appear effective in 
the treatment of FD through the normalization of gastric 
microbiota. The finding of an FD-type phylum profile can be 
used to characterize patients with FD and may serve as an 
objective biomarker for both the diagnosis and treatment of FD. 
Probiotics could be effective treatment for the indigestion via 
the reduction of Escherichia/Shigella, major source of toxic 
lipopolysaccharides in the upper GIT [98]. 
 
Constipation 
Constipation is a common gastrointestinal problem, which 
causes many expenses for the community with an estimated 
prevalence of 1% to 80%, worldwide. Various factors are 
involved in the pathogenesis of the disease, including type of 
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diet, genetic predisposition, colonic motility, absorption, social 
economic status, daily behaviors, and biological and 
pharmaceutical factors. Acute constipation may cause closure 
of the intestine, which may even require surgery.  Chronic 
constipation is a complicated condition among older 
individuals, which is characterized by difficult stool passage 
[87]. To better characterize the condition, physicians conceive 
constipation objectively using defecation frequency, with a 
normal range of between three and 21 bowel movements per 
week [94]. Factors that may contribute to functional 
constipation include pain, fever, dehydration, dietary and fluid 
intake, psychological issues, toilet training, medicines, and 
family history of constipation [88]. Pathogenesis is 
multifactorial with focusing on the type of diet, genetic 
predisposition, colonic motility, and absorption, as well as 
behavioral, biological, and pharmaceutical factors. 
Furthermore, low fiber dietary intake, inadequate water intake, 
sedentary lifestyle, IBS, failure to respond to urge to defecate, 
and slow transit have been revealed to be associated with 
predisposition [87,90]. About 30% of the general population 
experiences problems with constipation during life time. with 
elderly people and women being mostly affected. Constipation 
is also reported to occur in 2% to 25% of healthy people, but 
the incidence sometimes rises to 80% in critically ill patients 
[101]. 
 
 
Figure 3.  Initial management of acute primary constipation (symptoms <3 months) (Source: Constipation in adults: Treatment Practice. BMJ Best 
Practice). When constipation presents acutely, it is important to consider possible secondary causes, including colorectal cancer. Further 
investigations may be performed to exclude secondary causes. Enemas, suppositories, large volume polyethylene glycol solution (PEG), stimulant 
laxatives, or disimpaction with sedation may be required if there is fecal impaction. If fecal impaction is absent and secondary causes are excluded, 
the treatment is the same as for patients with chronic constipation. Initial steps in the management of chronic primary constipation are: Patient 
education; Lifestyle modifications; High-fiber diet; Increased fluid; Regular exercise; Bulk laxatives.  Dietary and lifestyle changes may be helpful. 
Patients are advised to increase their daily dietary fiber and calorie intake (in patients with low caloric intake). Patients are advised on adequate fluid 
intake and encouraged to get regular nonstrenuous exercise. Modest exercise can help relieve constipation, especially if patients are sedentary or 
generally inactive. Patients are advised to dedicate time for bowel movements and to avoid postponing bowel movements when an urge for 
defecation is felt. 
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Exhibit 4. Common causes of secondary constipation [90] 
Drugs 
Anabolic steroids, analgesics, opioids (codeine), NSAIDs, anticholinergics, anticonvulsivants, antidepressants, 
antihistamines, antihypertensives (verapamil e clonidine), anti-Parkinsonian, diuretics, antiacids containing calcium or 
alluminium, cholestyramine. 
Neuropathic and 
myopathic disorders 
Amyloidosis, Chagas disease, connective tissue disorders, CNS lesions, autonomic diabetic neuropathy, Hirschprung’s 
disease, multiple sclerosis. 
Idiopathic Paraneoplastic syndromes, Parkinson’s disease, dementia, scleroderma, post-viral colon-paresis, intestinal pseudo-obstruction, spinal or ganglion tumor, ischemia. 
Electrolytic balance 
alterations Hypokalemia, hypercalcemia 
Organic intestinal 
diseases 
Obstruction/stenosis: adenoma, cancer, diverticolitis, rectocele, hernia, foreign bodies, faecal impaction, IBD and 
complications. 
Anorectal abnormalities: anal stenosis or fissures, proctitis, rectocele, haemorrhoids. 
 
Hypothyroidism, diabetes mellitus, pregnancy and childbirth, dehydration, low fibers intake diet, hyperglycemia Endocrine-metabolic 
causes 
 
Prevalence and Economic Burden 
Functional constipation is a prevalent condition in childhood, 
about 29.6% worldwide. Up to 84% of functionally constipated 
children suffer from fecal incontinence, while more than one-
third of children present with behavioral problems primary or 
secondary due to constipation [88]. However, only a minority 
of patients (approximately 25 %) uses medical treatments, 
whereas a considerable proportion relies on alternative 
solutions, following advices given in pharmacies or herbalist’s 
shops [91,92]. A population-based study of outpatient clinic and 
emergency department visits found outpatients taking five or 
more drugs had an 88% increased risk of experiencing an 
adverse drug effect compared to those who were taking fewer 
drugs [93]. According to reports from Western countries, the 
prevalence of CC in the general population ranges from 2% to 
28%, with an increasing trend over years. Moreover, severe 
constipation is frequently observed in elderly women, with 
rates of 2 to 3 times higher than that of their male counterparts 
[95]. FGIDs, including chronic constipation (CC), are among the 
most frequent illnesses seen by gastroenterologists and 
account for up to one-half of patient care time (1). CC is a 
remarkably common and costly condition that can negatively 
impact the QoL, and result in a major social and economic 
burden [96]. 66,287 people in the UK were admitted to hospital 
with constipation as the main condition in 2014/15, equivalent 
to 182 people a day. 48,409 were unplanned e emergency 
admissions (this is equivalent to 13 3 per day). The total cost to 
hospitals for treating unplanned admissions due to constipation 
was £145 million in 2014/15. The figure is likely to be much 
higher for total NHS expenditure on constipation when 
including GP visits, home visits and prescriptions. The 
prescription cost of laxative costs is £101 million (Over the 
counter costs of laxatives will undoubtedly be higher). 1 in 7 
adults are affected by constipation at any one time in UK [97]. 
Pregnancy predisposes women to developing constipation 
owing to physiologic and anatomic changes in the 
gastrointestinal tract. For instance, rising progesterone levels 
during pregnancy and reduced motilin hormone levels lead to 
increases in bowel transit time. Also, there is increased water 
absorption from the intestines, which causes stool to dry out. 
Decreased maternal activity and increased vitamin 
supplementation (eg, iron and calcium) can further contribute 
to constipation. Later in pregnancy, an enlarging uterus might 
slow onward movement of feces. Constipation can result in 
serious complications such as fecal impaction, but such 
complications are rare [107]. 
 
Herbs and Probiotics for Constipation 
Cascara sagrada used (hydroxyanthraquinone glycosides found 
in the dried bark) to be approved by the U.S. FDA as an OTC 
drug for constipation. However, over the years, concerns were 
raised about its safety and effectiveness (causes nausea, 
vomiting and griping abdominal pain) [98-100]. Psyllium is the 
most commonly used bulking agent in Canada. In placebo-
control trials, psyllium has been shown to decrease stool transit 
time, and improve stool frequency, consistency and weight; 
when psyllium was compared with lactulose, the magnitude of 
effects on stool frequency was similar, associated benefit of 
dietary fiber in reducing coronary heart disease and lowering 
low-density lipoprotein cholesterol, it is generally 
recommended as the initial conservative treatment for chronic 
constipation [100]. Recently, maintenance of intestinal motility 
has become an important issue in intensive-care medicine. 
Although drugs such as metoclopramide, erythromycin, 
neostigmine, and others are reported to resolve incompetent 
intestinal motility [101], there are problems with drug 
tolerance. Rhubarb has been widely used as a traditional 
Chinese herbal medicine since ancient times. Sennoside A and 
other dianthrone derivatives are reported to be the active 
ingredients causing rhubarb's laxative effect. To induce its 
laxative effect, rhubarb needs to be metabolized to rhein 
anthrone by β-glucosidase, which is produced by gut microbiota 
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[102]. Improvement in intestinal motility can prevent sepsis of 
gut origin [103]. Rhubarb contains dianthrone glucosides 
(sennosides A to F) and anthraquinones (e.g., rhein, aloe-
emodin, emodin, physcion, chrysophanol); Among these 
components, sennosides (i.e., stimulant laxatives), have been 
well documented for their pharmacological action on 
constipation [104]. Senna is used to treat constipation and clear 
the bowel before some medical procedures.it should only be 
used in the short term and at the recommended doses. Long-
term and high-dose use has been reported to cause liver 
damage [105]. Senna induced dermatitis is rare, but may occur 
when patients need a higher dose. Pediatric caregivers should 
advise families of the rare side effect of skin blistering and 
educate them to change the diaper frequently in children who 
are not toilet- trained to reduce stool to skin exposure. Senna is 
a safe treatment option for constipation in children [106]. Until 
more data are available, the use of probiotics for the treatment 
of constipation should be considered investigational. Current 
ESPGHAN/NASPGHAN recommendations that probiotics 
should not be used in the treatment of functional constipation 
in children [113]. The bacterial endotoxin lipopolysaccharide 
may influence intestinal motility by delaying gastric emptying 
and inducing sphincteric dysfunction. Human colonic gases 
produced by microflora may also be associated with changes in 
gut motility. For example, breath methane excretion in patients 
with slow-transit constipation was greater than in healthy 
subjects or patients with normal-transit constipation, 
supporting the idea that methane can slow gut transit. 
Collectively, the altered intestinal microbiota may play an 
essential role in the pathogenesis of chronic constipation [114].  
 
Exhibit 5. Summary of randomized controlled trials of probiotics for the management of chronic constipation [114] 
Population Intervention Comparator Author’s conclusion 
n = 159 (control n = 80, intervention n = 79) B. lactis DN-173 010 
Acidified milk without 
probiotics 
Increased stool frequency, but not statistically 
significant compared with control group 
n = 44 (control n = 22, intervention n = 22) L. reuteri DSM 17938 Identical placebo Increased bowel frequency 
n = 30 (control n = 15, intervention n = 15) B. lactis Bi-07 Fresh cheese without probiotics Beneficial effects 
n = 126 (control n = 63, intervention n = 63) B. lactis DN-173010 
Acidified milk without 
probiotics 
Beneficial effects on stool frequency, defecation 
condition and stool consistency 
n = 17 (cross-over design) B. lactis GCL2505 Milk-like drink Beneficial effects 
n = 100 (control n = 34, Intervention: high 
dose n = 33 low dose n = 33) B. lactis HN019 
Capsules with rice 
maltodextrin 
Decreased whole gut transit time in a dose-dependent 
manner 
n = 90 (control n = 43, intervention n = 47) L. casei Shirota Fermented milk without probiotics Improvement in constipation severity 
n = 20 (cross-over design) L. paracasei IMPC 2.1 
Artichokes without 
probiotics Beneficial effects 
n = 70 (control n = 35, intervention n = 35) L. casei shirota Beverage without probiotics 
Beneficial effects on self-reported severity of 
constipation and stool consistency 
 
Herbs in Pregnancy Induced Constipation 
It has been estimated that approximately 11% to 38% of 
pregnant women experience constipation, which is generally 
described as infrequent bowel movements or difficult 
evacuation [107]. The prevalence of herbal medicine utilization 
in pregnancy ranges between 7% and 55% in different 
geographical, social and cultural settings, and ethnic groups 
[108]. The majority of the studies reported the highest use of 
herbs during the first trimester with the frequency varying from 
17.3% to 67.5% in Middle East [107]. It is a well-documented 
fact that the risk in pregnancy is unknown for 91.2% of the 
approved medications. The use of herbal products which are 
not usually tested in clinical trials during pregnancy could result 
in immense risk to the mother and fetus [109,110]. Since herbal 
medicines are a part of traditional medicine, they are not 
included in the FDA pregnancy categories giving a false 
impression of safety. The whole extracts of these herbal drugs 
contain numerous active molecules that could elicit adverse 
effects including teratogenicity [111,112]. 
 
Irritable Bowel Syndrome (IBS) 
IBS is present in patients with symptoms of chronic abdominal 
pain and altered bowel habits but no identifiable organic 
etiology [113]. Patients with IBS often associate their symptoms 
to certain foods [115]. In CSID, recessive mutations in the SI 
gene (coding for the disaccharidase digesting sucrose and 60% 
of dietary starch) cause clinical features of IBS through colonic 
accumulation of undigested carbohydrates, triggering bowel 
symptoms [116]. Diagnosing IBS can be challenging due to the 
nonspecific nature of symptoms, overlapping upper and lower 
abdominal symptoms, and the frequent presence of somatic 
and psychological comorbidities. Despite these guidelines, 
there remains low awareness and little consensus on the use of 
diagnostic tests and surgical procedures in IBS. Furthermore, 
although surgery has no role in the recommended treatment 
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approach for IBS, multiple studies have reported that this 
patient population is predisposed to unnecessary surgical 
procedures, suggesting a disconnect between the 
recommended best practices and real-world management of 
IBS [117]. Under certain ambiguous circumstances, an exclusive 
and pure diagnosis of IBS cannot be achieved because of food-
dependent symptoms: in fact, up to 80% of IBS patients identify 
food as a possible trigger for their symptoms, so they 
increasingly ask for dietary and behavioral counseling [118]. 
Common practices for IBS management begin with diet and 
lifestyle modification, and in more severe cases, 
pharmacotherapy (e.g. antidepressants, smooth muscle 
antispasmodics, or secretagogues) [119]. 
 
 
 
 
 
 
 
 
Figure 4. Clinical overlap between IBS and IBS-like disorders. IBS; 
FODMAPs; SIBO; NCGS; ATIs; Ni ACM. FODMAPs have been shown to 
share clinical characteristics and trigger foods with both lactose 
intolerance and Ni ACM. Specifically, many foods rich in FODMAPs are 
also high in lactose. Given the high prevalence of lactose intolerance, 
it is not surprising that a diet low in FODMAPs may reduce or even 
resolve gastrointestinal and extra-intestinal symptoms. The same 
thing can be true for foods rich in Ni, very numerous in the FODMAPs 
family, such as pears, cabbage, garlic, onion and legumes. Another 
important intersection exists between FODMAPs and NCGS, or even 
better between Ni ACM and NCGS: upon closer analysis, symptoms of 
suspected NCGS patients are actually triggered by associated Ni-rich 
ingredients or condiments (e.g. yeast or tomato), and not by gluten 
itself. As a consequence, foods such as bread, pasta with tomato sauce, 
pizza and bakery products turn into real traps for Ni-sensitive and/or 
lactose intolerant patients, in defiance of the Mediterranean diet, 
recently declared part of the UNESCO's Intangible Heritage List. 
 
Prevalence and Economic Burden 
IBS affects both men and women of all ages. It is thought only a 
fraction of individuals with symptoms of IBS seek medical 
attention. The prevalence of IBS globally is 11%, however, it is 
thought that IBS often remains underdiagnosed. A survey of 
patients with IBS (both with and without a formal diagnosis) 
conducted by the Gastrointestinal Society in Canada showed 
that 46% had missed work or school due to IBS symptoms [120]. 
Its estimated prevalence is 10%–20%, although marked 
variation may exist based on geographical location; for 
example, its prevalence is 21% in South America versus 7% in 
Southeast Asia. It is nearly twice more common in women than 
men [118]. Various studies have reported prevalence to be 
approximately 8 to 12% in children, and 5 to 17% in adolescents 
[125]. IBS causes a significant burden on healthcare systems, 
due in part to the high level of HRU associated with IBS. Direct 
medical costs attributed to IBS in the US, excluding prescription 
and OTC medicines, were estimated at US $1.5–$10 billion per 
year in 2005. According to University at Buffalo, the economic 
burden of IBS in the U.S. is estimated at $28 billion annually 
[124]. A portion of these costs may be related to unnecessary 
and high-frequency tests, although few studies have assessed 
the factors underlying frequent tests and procedures among 
patients with IBS [117]. In IBS, it has been reported that 50% to 
90% of patients have or had at some point one or more 
common psychiatric condition, including major depressive 
disorder, generalized anxiety disorder, social phobia, 
somatization disorder, or posttraumatic stress disorder [123]. 
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Exhibit 6. Subtypes of IBS are recognized by the Rome IV criteria based on the person’s reported predominant bowel habit, 
when not on medications [118], [120-122] 
IBS-C With predominant constipation. The symptoms most frequently reported for IBS-C are:  abdominal pain, bloating 
and constipation. 32% of IBS-C respondents reported feeling depressed because of their condition almost every 
day in the previous month. HRQoL for those with IBS-C is low compared to those with chronic conditions such as 
diabetes, heart failure and heart defects, who have a high rate of mortality, and also those with asthma, migraine 
and rheumatoid arthritis, with well-known morbidity. 
IBS-D With predominant diarrhea. The symptoms most frequently reported for IBS-D are:  abdominal pain and 
discomfort, abdominal bloating, distension, urgency and diarrhea. 47% of respondents with IBS-D stated that 
they had little or no ability to predict their symptoms on a   daily basis. When asked how IBS-D affects them, 81% 
stated that they avoided situations where there was no nearby washroom. 
IBS-M With both constipation and diarrhea. In the United States, patients are equally distributed among IBS with 
diarrhea (IBS-D), IBS with constipation (IBS-C), and IBS with a mixed bowel pattern (IBS-M), whereas in Europe, 
studies have found either IBS-C (45.9%) or IBS-D (50%) as the main pattern group. IBS-M is a heterogeneous 
symptom group and thus requires that subclassification criteria be better defined. Use of laxative/antidiarrheal 
medications adds to the diagnostic complexity in a potentially more severe subset of IBS-M and should be 
assessed for accurate subclassification. 
IBS-U Un-subtyped IBS, has a lower prevalence (17.8%). Un-subtyped IBS subjects had the highest HR-QOL compared to 
other subtypes. 
 
Lifestyle Modification 
An important lifestyle adjustment that should be 
recommended to IBS patients is regular exercise. Mild exercise 
or physical activity has been shown to reduce IBS symptoms 
and alleviates bloating and gas production in several studies. 
Since regular exercise also helps to increase gastrointestinal 
motility it is beneficial in IBS-C patients with primary low GI 
movement and hard stools. As part of exercise, yoga has been 
investigated due to its low impact on joints and its relatively 
targeted postures that can help to reduce GI symptoms. 
Pranayama yoga administered twice daily has been shown to 
increase sympathetic tone and may benefit IBS-D patients that 
present with decreased sympathetic activity to the same 
degree than daily loperamide administration in the control 
group [127]. Fiber is defined as non-starch polysaccharides in 
agreement with FAO/WHO/DOH measurement methods. It 
includes β-glucans, pectins, gums, mucilages and some 
hemicelluloses. Dietary sources include oats, psyllium, 
ispaghula, nuts and seeds, some fruit and vegetables and 
pectins. An increase in fiber has often been suggested as an 
initial treatment for IBS [131]. 
 
 
Figure 5. IBS Dietary Treatment Pathway. In the last 10 years, evidence has emerged for the restriction of a group of short chain fermentable 
carbohydrates which have collectively become known as FODMAPs. The common factor in these foods is the size and chain length of these 
carbohydrate molecules, as they all contain between 1 and 10 glucose molecules. This group of short-chain carbohydrates is susceptible to colonic 
fermentation by a number of possible mechanisms, which have been shown to exacerbate IBS symptoms. There is strong evidence to support three 
mechanisms of action: 1. Augmentation of small intestinal water 2. Increased colonic fermentation 3. Immune modulation (Source: Jankovich E, 
Watkins A. Case Study: The low FODMAP diet reduced symptoms in a patient with endometriosis and IBS. S Afr J Clin Nutr 2017;30(4):32-36). 
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Herbs and Probiotics for IBS 
Pharmacological treatment of IBS varies from antidepressants 
including tricyclic antidepressants and selective serotonin 
reuptake inhibitors, to antispasmodics, 5-HT3 antagonists, 5-
HT4 agonists, antibiotics, probiotics, and melatonin. But 
involvement of numerous factors in pathophysiology and a very 
significant placebo effect cause therapy of this disease to be 
more complex. Due to disappointing results with conventional 
IBS treatments, complementary and alternative medicines are 
becoming attractive options for many patients [126]. CAM 
alone and in conjunction with pharmacological treatments as 
an integrative approach to manage patients with IBS and 
improve their quality of life. Prokinetics are not specific to IBS 
and increase gastrointestinal motility in general by acting via 
dopamine and 5-HT3 receptors as antagonists or 5-HT4 
receptors as agonists. Lubiprostone, a 5-HT4 agonist, has been 
recently approved to treat IBS-C in women through activation 
of chlorine channels leading to increased water secretion into 
the lumen which decreased transit time and associated visceral 
pain in patients. The common use of 5-HT3 receptor 
antagonists such as ondansetron and granisetron to reduce 
visceral pain perception in IBS-D patients has shown some 
benefits but is also limited by side effects [127]. Novartis has 
agreed to continue to supply Zelnorm® (Tegaserod maleate) for 
use in emergency situations, due to an increased cardiovascular 
risk [128,129]. Glaxo Wellcome (Now GSK) has informed the US 
FDA that it will voluntarily withdraw Lotronex® (alosetron) 
tablets (for IBS-D) from the market [130]. Clinical benefits of 
supposed spasmolytic (anti-spasmodic) agents may relate more 
to effects on visceral sensation than motility. A mixture of dried 
powdered slippery elm bark, lactulose, oat bran, and licorice 
root significantly improved both bowel habit and IBS symptoms 
in patients with constipation-predominant IBS [132]. There is a 
growing body of evidence which indicates therapeutic 
properties for ALE. Furthermore, 96% of patients rated ALE as 
better than or at least equal to previous therapies administered 
for their symptoms, and the tolerability of ALE was very good 
[133]. In IBS, the gastrointestinal flora may undergo both 
qualitative and quantitative changes and the most common 
finding is a decrease in the population of ‘good bacteria’ such 
as Bifidobacteria and Lactobacilli and the faecal microflora has 
increased numbers of facultative organisms. Probiotics may be 
useful in the management of IBS, however dose and specific 
bacterial strain are important. In vivo studies have identified 
some of the variables that determine the survival of probiotics 
through the GI tract, and some have attempted to quantify the 
degree of survival of the dose administered. This was found to 
vary from 10 to 50% depending on the probiotic species used 
and the dose administered [131]. 
 
 
Exhibit 7. Herbs used for treatment of irritable bowel syndrome [125], [127]  
Herbal medicine Type of study Results 
Artichoke (Whole plant) Post-marketing surveillance 
study 
Significant reductions in the severity of symptoms 
Open dose-ranging study “Alternating constipation/diarrhea” toward “normal”, significant 
improvement in total quality-of-life (QOL) score 
Fumaria officinalis 
(Whole plant) 
Double-blind, placebo-RCT No difference between treatment and placebo groups 
Curcuma longa (Rhizome) Pilot study, partially blinded, 
RCT randomized, 
No difference between treatment and placebo groups 
Iberogast ®  Randomized, double-blind, 
placebo-controlled 
Significantly improves quality of life and reduces abdominal pain in IBS 
patients 
Hypericum perforatum 
(HP) (Aerial parts) 
Open-label, uncontrolled trial Autonomic nervous system to different stressor, improvement of 
Gastrointestinal symptoms of IBS 
Double-blind, placebo-RCT No difference between treatment and placebo groups 
Mentha piperita (MP) 
(Oil/Essence) 
Double-blind, placebo-RCT Peppermint-oil was effective and well tolerated 
Prospective double-blind, 
placebo-RCT 
Improves abdominal symptoms 
Double-blind, placebo-RCT Significantly improved the quality of life, improves abdominal symptoms 
Plantago psyllium (Seed) Placebo, RCT Decrease Symptom severity significantly in the psyllium group, no 
differences in QOL 
Carmint (Mentha spicata 
leaf, Melissa officinalis 
leaf, Coriandrum sativum 
fruit) 
Double-blind, placebo-RCT Severity and frequency of abdominal pain/discomfort were significantly 
lower in the Carmint group than the placebo group 
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Inflammatory Bowel Disease (IBD) 
IBS, a common gastrointestinal disorder involving the gut-brain 
axis; IBD, a chronic relapsing inflammatory disorder. Both have 
significant overlap in terms of symptoms, pathophysiology, 
and treatment, suggesting the possibility of IBS and IBD being 
a single disease entity albeit at opposite ends of the spectrum 
[133]. A significant association between IBD and later 
occurrence of PD, which is consistent with recent basic 
scientific findings of a potential role of GI inflammation in 
development of parkinsonian disorders [134]. An area of 
recent research interest where the role of adiposity is avidly 
discussed is in IBD, which presents mainly as Crohn's disease 
(CD) and ulcerative colitis (UC) [135]. IBD is a chronic illness, 
and sexual dysfunction is a well-recognized complication of 
chronic illness [136]. A subgroup of IBD patients considered 
diet to be a more important and successful managing tool than 
medication to relieve their disease symptoms [137].  
 
 
 
Figure 6. Environmental triggers in IBD. A wide variety of 
environmental triggers have been associated with IBD pathogenesis, 
including the gut microbiota, diet, pollution and early-life factors. 
Smoking remains the most widely studied and replicated risk factor, 
contributing to increased risk and severity of CD while conferring 
protection against UC. Lower plasma vitamin D is associated with an 
increased risk of Crohn’s disease, and vitamin D supplementation may 
prevent relapse of disease. Several medications including oral 
contraceptives, post-menopausal hormone replacement, aspirin, 
NSAIDs, and antibiotics may increase risk of CD or UC with the 
mechanisms of effect remaining inadequately defined. There is 
continuing evidence that depression and psychosocial stress may play 
a role in the pathogenesis of both CD and UC, while at the same time 
also increasing risk for disease flares. There is also a growing 
understanding of the role of diet on IBD, in particular through its 
effect on the microbiome. Animal protein intake and n-6 fatty acids 
may increase risk of UC while n-3 fatty acids and dietary fiber may 
confer protection. The effect of diet on established disease remains 
poorly studied. There is need for routine measurement of a spectrum 
of environmental exposures in prospective studies to further our 
understanding (Source: Ananthakrishnan AN. Environmental triggers 
for inflammatory bowel disease. Curr Gastroenterol Rep. 
2013;15(1):302). 
 
 
 
 
Prevalence and Economic Burden of IBD 
IBD, including UC and CD, are chronic, disabling, and 
progressive disorders characterized by lifelong treatment and 
whose incidences are increasing in Asia [141]. EIMs of IBD 
occur in up to 55% of patients with CD and 35% of those with 
UC. Although arthritis/arthralgia is the most common EIM in 
both disorders, multiple organs may be affected including skin, 
eye and liver [145]. Approximately 2.5 million–3 million people 
in Europe are affected by IBD. The highest rates of IBD are 
reported in Scandinavia and the UK. The incidence and 
prevalence of UC in the UK is estimated to be 14 cases per 
100,000 person-years and 244 cases per 100,000 people, 
respectively. The incidence and prevalence of CD in the UK is 
estimated to be 7-11 per 100,000 and 85–145 cases per 
100,000 people, respectively [144]. An increasing number of 
these children are being treated with immunosuppressive and 
biological medications. Although these medications can 
improve the short-term outcome and quality of life of children 
with IBD, they have been associated with opportunistic 
infections, malignancy, and lymphoproliferative disorders 
among IBD populations. It is estimated that 15% to 20% of all 
cases of IBD are diagnosed in the childhood and adolescent 
period [146]. Patients with IBD have a 2- to 3-fold increased 
risk of colorectal cancer death; therefore, colorectal cancer 
surveillance via colonoscopy is recommended for IBD patients 
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[147]. Environmental factors probably have a major role in IBD; 
antibiotic use, childbirth mode, breastfeeding, air pollution, 
NSAID use, hypoxia or high altitude, diet and urban 
environments have been studied [148]. 
 
Rationale of DS and Probiotics in IBD 
A recent survey by de Vries et.al., 2019, DS were used by 68% 
of the IBD patients. Although over 71% had received dietary 
advice mainly by dieticians, 81% stated that the main source of 
their nutritional knowledge related to IBD was their own 
experience [137]. Despite recent advancements, Crohn's 
disease and ulcerative colitis remain chronic and progressive 
diseases. One of the primary reasons for persistent 
inflammation and bowel damage is failure of medical therapy. 
With growing therapeutic options, there is an increased 
temptation to quickly move to the next therapy and label the 
prior therapy as a failure; however, this can lead to inadequate 
optimization of medications and poor control of disease. On 
the other hand, failure to recognize ongoing mucosal 
inflammation despite optimized treatment and moving to the 
next agent can lead to progression of disease and long-term 
complications [138]. Anti-tumor necrosis factor antibodies 
have led to a revolution in the treatment of IBD; however, a 
sizable proportion of patients does not respond to therapy. 
There is increasing evidence suggesting that treatment failure 
may be classified as mechanistic (pharmacodynamic), 
pharmacokinetic, or immune-mediated. Data regarding the 
contribution of these factors in children with IBD treated with 
infliximab (IFX) are still incomplete [139]. Endoscopic therapy 
has been explored and used in the management of strictures, 
fistulas/abscesses, colitis-associated neoplasia, postsurgical 
acute or chronic leaks, and obstructions [140]. For several 
decades, medical treatments for IBD were limited to non-
biological therapies (i.e., aminosalicylates, thiopurines, and 
steroids), which provide symptomatic improvement but do not 
change the disease course [141]. Anti-TNF agents (infliximab, 
adalimumab, and certolizumab) have reduced the need for 
surgery and hospitalization and have improved the quality of 
life of patients by changing the course of the disease. Thus, 
guidelines recommend the use of anti-TNF agents initially in 
moderate-to-severe IBD or if non-biological therapy fails. 
However, these treatments have not been effective in all 
patients, and patients who initially responded to treatment 
have also lost their responsiveness over time. Furthermore, 
although anti-TNF agents are generally well tolerated, their use 
is associated with adverse effects, including risks of infection 
and malignancies [142,143]. 
 
Use of Herbs and Probiotics 
The use of herbal therapy in IBD is increasing worldwide. It can 
be assumed that the efficacy of herbal therapies in IBD is 
promising. The most important clinical trials conducted so far 
refer to the use of mastic gum, tormentil extracts, wormwood 
herb, triticum aestivum, germinated barley foodstuff, and 
boswellia serrata.  In ulcerative colitis, Triticum aestivum, 
Andrographis paniculata extract and topical Xilei-san were 
superior to placebo in inducing remission or clinical response, 
and curcumin was superior to placebo in maintaining 
remission; boswellia serrata gum resin and plantago ovata 
seeds were as effective as mesalazine, whereas oenothera 
biennis had similar relapse rates as ω-3 fatty acids in the 
treatment of ulcerative colitis. In Crohn’s disease, mastic gum, 
Artemisia absinthium, and Tripterygium wilfordii were 
superior to placebo in inducing remission and preventing 
clinical postoperative recurrence, respectively [149].  
 
Exhibit 7. Herbs used for treatment of IBD 
Herbal medicine Type of study Ref No. Results 
Triticum aestivum 
(Poaceae) 
randomized, double-
blind, placebo-
controlled study 
150 Treatment was associated with significant reduction in the overall 
disease activity index and in the severity of rectal bleeding. Apart 
from nausea, no other serious side effects were noticed 
Andrographis 
paniculata 
Randomized, double-
blind multicentre study 
151 Compared with Mesalazine (4.5 mg/day), there were no significant 
differences between the two treated groups when considering the 
clinical efficacy rates or the safety profile  
Boswellia serrata 
(Burseraceae) 
Single Centered study 152 Compared with Sulfasalazine, all parameters tested improved after 
treatment with Boswellia serrata gum in 82% patients 
Artemisia absinthium Randomized, double-
blind multicentre study 
153 Compared with placebo, after 8 weeks of treatment with wormwood, 
there was almost complete remission of symptoms in 65% of the 
patients, 
Tripterygium 
wilfordii Hook F 
(TWHF) 
Randomized controlled 
trials 
154 Patients receiving mesalazine experienced less adverse events, but no 
significant difference was found about ADEs resulted withdrawal in 
the 3 groups. In addition, compared with low-dose TwHF and 
mesalazine, the authors also detected significant superiority of high-
dose TwHF arm in the decrease of CDAI and SESCD  
Evening primrose oil 
Oenothera biennis 
Randomized controlled 
trials 
155 Oenothera biennis had similar relapse rates as omega-3 fatty acids in 
the treatment of UC 
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Altered gut bacteria and bacterial metabolic pathways are two 
important factors in initiation and progression of IBD. 
However, efficacy of probiotics in remission of patients with 
IBD has not been characterized [156]. Among the effects 
claimed for probiotics are beneficial immunomodulation, 
reduction of serum cholesterol, improved lactose digestion 
and protection against colon cancer [157,158]. Probiotic 
administration improved the clinical symptoms, histological 
alterations, and mucus production in most of the evaluated 
animal studies, but some results suggest that caution should 
be taken when administering these agents in the relapse 
stages of IBD [158]. In CD, the entire gastrointestinal tract can 
be involved and the inflammation can extend through the 
intestinal wall from mucosa to serosa. Areas of inflammation 
may be interspersed with relatively normal mucosa. In CD, the 
predominant symptoms are diarrhea, abdominal pain and 
weight loss whereas in UC diarrhea is the main symptom, often 
accompanied by rectal bleeding. Both diseases are common in 
the industrialized world, with highest incidences in North 
America and Northern Europe [159].
 
 
Exhibit 8. Summary of probiotic anti-inflammatory effects in In Vitro studies. [160] 
Cell Type Probiotic Strain Type of Study Main Outcome 
human DC L. casei Shirota In vitro 
DC from UC patients samples have an increase of IL-4 production 
and loss of IL-22 and IFN-γ secretion. L. casei Shirota treatment 
restored the normal stimulatory capacity through a reduction in the 
TLR-2 and TLR4 expression  
IPEC-J2 model L. plantarum strain CGMCC1258 In vitro 
L. plantarum decreased transcript abundances of IL-8, TNF-α, and 
negative regulators of TLRs. Moreover, L. plantarum treatment 
decreased the gene and protein expression of occludin 
PIE cells L. delbrueckii subsp. delbrueckii TUA4408L In vitro 
The activation of MAPK and NF-κB pathways induced by E. coli 987P 
were downregulated through upregulation of TLR negative 
regulators, principally by TLR2 
IEC-6 E. coli Nissle 1917 and L. rhamnosus GG In vitro 
Pre-treatment with these probiotics could prevent or inhibit 
enterocyte apoptosis and loss of intestinal barrier function induced 
by 5-FU 
DC 
L. paracasei CNCM I-4034, 
B. breve CNCM I-4035, and 
L. rhamnosus CNCM I-4036 
In vitro Induction of TLR-9 expression and TGF-β2 secretion. CFS treatment decreased the pro-inflammatory cytokines and chemokines 
 
Peptic Ulcer Disease (PUD) 
The presenting symptoms of PUD vary depending on the age of 
the patient. Hematemesis or melena is reported in up to half of 
patients with PUD. Infants and younger children usually present 
with feeding difficulty, vomiting, crying episodes, hematemesis, 
or melena [161]. The major symptom of uncomplicated PUD is 
upper abdominal dyspepsia such as bloating, early satiety, and 
nausea. H. pylori infection plays a crucial role in the 
pathogenesis of PUD. H. pylori infection is involved in various 
gastroduodenal pathologies, and evokes the production of 
proinflammatory interleukin-1beta, leading to the reduction of 
blood flow to the gastroduodenal tract and increasing the risk 
of peptic ulcers. H. pylori can colonize not only in the stomach, 
but also in the oral cavity. The oral cavity may be a reservoir for 
H. pylori and a potential source for infection of the stomach 
[162]. EGD is most accurate diagnostic test with sensitivity and 
specificity up to 90% in diagnosing gastric and duodenal ulcers. 
Surgical treatment is indicated if the patient is unresponsive to 
medical treatment, noncompliant or at high risk of 
complications. Surgical options include vagotomy or partial 
gastrectomy [163]. Factors that increase risk of developing 
peptic ulcer include smoking, older individuals, O blood type, 
and stress. Peptic ulcers that tend to heal longer than duodenal 
ulcer is at higher risk of developing gastritis and gastric 
malignancy [168]. Classically, patients with duodenal ulcers 
complain of worsening abdominal pain on an empty stomach 
and describe hunger or abdominal pain two to three hours after 
meals or at night. In contrast, patients with gastric ulcers report 
nausea, vomiting, weight loss and post-prandial abdominal 
pain. Elderly patients are often minimally symptomatic and 
some patients with untreated PUD may have intermittent 
symptoms due to spontaneous healing and then relapse due to 
persistence of risk factors, such as continued NSAIDs use or H. 
pylori infection [169].  
 
Prevalence and Economic Burden of PUD 
The prevalence of PUD ranges from 0.12 to 1.5% and increases 
with age [162]. H. pylorus is a gram-negative bacillus that is 
found within the gastric epithelial cells. This bacterium is 
responsible for 90% of duodenal ulcers and 70% to 90% of 
gastric ulcers, up to 85% of individuals infected with H. pylori 
are asymptomatic and have no complications [163], [165]. PUD 
is a global problem with a lifetime risk of development ranging 
from 5% to 10% [164]. In many studies worldwide (United 
States, Brazil and China), the prevalence of H. pylori among 
subjects with dyspepsia was 28.9%, 57%, and 84% respectively 
[165]. The prevalence differs in the world population between 
the duodenal and gastric ulcers, and the mean age of people 
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with the disease is between 30 and 60 years, but it can happen 
in any age [166]. Environmental elements such as alcohol and 
nicotine can inhibit or reduce secretion of mucus and 
bicarbonate, increasing acid secretion. Genetic factors can 
influence, and children of parents with duodenal ulcer are three 
times more likely to have ulcer than the population [167]. 30% 
PUD patients are smoker [168]. NSAIDs account for over 90% of 
all ulcers and approximately 25% of NSAID users will develop 
peptic ulcer disease [169]. Approximately 500,000 persons 
develop PU in the United States each year [170]. Peptic ulcers 
accounted for 301,000 deaths in 2013, which is down from 
327,000 deaths in 1990 [174]. Low socioeconomic status and 
concrete life difficulties are associated with peptic ulcer in the 
general population cross-sectionally and prospectively after 
adjustment for major physical risk factors, lending credence to 
a relationship between psychological stress and peptic ulcer 
[175].  
 
Lifestyle Modification for PUD 
The physicochemical properties of fiber fractions produce 
different physiological effects in the organism. Soluble fibers, 
found in apple, oatmeal, and pear are responsible, for instance, 
for an increased viscosity in the intestinal content. Insoluble  
 
 
 
 
fibers (whole grains, granola, flaxseed) increase stool bulk, 
reduce transit time in the large intestine, and make fecal 
elimination easier and quicker [171]. Physical activity has 
numerous health benefits and may also represent a cost-
effective approach to the prevention of peptic ulcers. At the 
levels observed in this study among the moderately active 
group (walking or jogging <10 miles a week), possible adverse 
effects—for example, injuries—are minimized. In the general 
population, only about a third of adults undertake this much 
physical activity. 
 
Strategies to promote safe walking, jogging, and cycling may 
benefit many aspects of health in addition to the cardiovascular 
and musculoskeletal systems [173]. Moderate physical activity 
could have a favorable impact on a number of risk factors for 
peptic ulceration. It could reduce gastric secretions and 
enhance immune function, with the latter reducing the risk of 
Helicobacter pylori infection. Moderate activity might also 
reduce anxiety and encourage the adoption of a healthy 
lifestyle, with avoidance of smoking and an excessive 
consumption of alcohol. However, prolonged endurance 
exercise seems likely to have a negative impact, suppressing 
immune function, reducing mucosal blood flow, and calling 
 for frequent administration of NSAIDs [176]. 
 
 
 
Exhibit 9. Allowed foods, foods that should be consumed with caution, and foods that must be avoided [172] 
Food groups Allowed  Use with caution Prohibited  
Dairy Milk, low-fat cheeses, yogurt, fermented milk Fatty cheeses (mascarpone, cream cheese, gorgonzola) - 
Oilseeds Flaxseed, Brazilian nut, walnuts  - - 
Oils and olive 
oils  Vegetable oils, olive oil - Fried foods 
Fruits Apple, papaya, melon, banana Orange, pineapple, acerola, passion fruit Lemon 
Vegetables Leafy dark green vegetables, carrot, beet, green bean, spinach, kale, radish, zucchini, leek  
Broccoli, cauliflower, cabbage, cucumber, onion, 
red pepper 
Spicy peppers (black 
pepper, chilies) 
Legumes Bean soup, lentils, chickpeas, soybean Beans - 
Meats Lean meat (beef, pork, chicken, fish) Fatty meats, organ meats and sausages - 
Sweets - Concentrated sweets Chocolate 
Beverages Natural juices Citrus/acidic fruit juices Coffee, black tea, fizzy/cola drinks  
Other foods - Industrialized seasonings, spices and condiments (Ketchup, mayonnaise, mustard) Mustard grain 
 
 
Herbs and Probiotics for PUD Management 
The potential of plants as source of new drugs still offers a large field for scientific research. Even if is observed a large number of 
known plants, a small percentage has already been phytochemically investigated and only a fraction of them has already been assessed 
to determine its pharmacological potential.  
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Exhibit 10. Herbs for PUD Management 
Plant name/family Description 
Acacia arabica (Mimosaceae) Locally known as babul tree. Aqueous extract of A. arabica gum showed protection against 
meloxicam‑induced intestinal damage and attenuated intestinal enzyme activity. Chemical constituents 
reported in this plant are gum containing arabic acid combined with calcium, magnesium, and potassium and 
also small quantity of malic acid, sugar, moisture 14%, and ash 3-4%. As gargle it is useful as wash in 
haemorrhagic ulcer and wounds [178]. 
Psidium guajava L., popularly 
known as guava (Myrtaceae) 
The leaves have shown the ability to protect the stomach against ulceration by inhibiting gastric lesions, 
reducing gastric secretory volume, and acid secretion, and raising the gastric pH. This anti-ulcer activity, 
resulting from the protection of the mucosa, was related to the flavonoids in the leaves [179] 
Aegle marmelos (Rutaceae), 
Bael Fruit 
Ulcers are induced by aspirin plus pylorus ligated gastric ulceration in rats and aqueous extract of leaves is to 
be administered orally for 21 days, daily dose of 1 gm/kg. The result indicated a significant reduction in the 
ulcer lesion count compared to control [180] 
Allium sativum 
(Liliaceae) garlic 
Chemical constituents in this plant arean acrid volatile oil which is the active principle, starch, mucilage, 
albumen, and sugar. Seeds yield aromatic oil. The juice, more particularly its oil constituents, is rich in 
organically bound sulphur, iodine, and salicylic acid combinations, apart from important nutrient and 
complementary substances containing vitamins [178]. Garlic extract has been also studied to show 
suppressive effect of Helicobacter pylori-induced gastric inflammation in vivo and reduction of gastric cancer 
incidence in a clinical trial [181]. AGE corrected the histopathological abnormalities in gastric tissue and 
proved (investigated in an experimental model of indomethacin-induced gastric ulcer) a promising 
gastroprotective role in gastric ulcer [182]. 
Azadirachta indica  
(Meliaceae) Neem 
Administration of lyophilized powder of the extract for 10 days at the dose of 30 mg twice daily showed 
significant decrease (77%) of gastric acid secretion. The bark extract at the dose of 30–60 mg twice daily for 10 
weeks almost completely healed the duodenal ulcers and one case of esophageal ulcer and one case of gastric 
ulcer healed completely when administrated at the dose of 30 mg twice daily for 6 weeks [184] 
Bauhinia purpurea L. 
(Fabaceae)  
Chemical constituents reported in this plant are quercetin, rutin, apigenin, and apigenin 7-0-glucoside. Bark 
contains tannin (tannic acid), glucose, and a brownish gum. The Bauhinia purpurea aqueous extract (BPAE) 
was prepared in the doses of 100, 500 and 1,000 mg/kg. Antiulcer activity of BPAE was evaluated by absolute 
ethanol- and indomethacin-induced gastric ulcer, and pyloric ligation models. Acute toxicity was also carried 
out. The BPAE exhibits antiulcer activity, which could be due to the presence of saponins or sugar-free 
polyphenols, and, thus, confirmed the traditional uses of Bauhinia purpurea in the treatment of ulcers [185] 
T. indica (Caesalpinioideae) 
Tamarind  
The methanolic extract of the seed coat of this plant (100 mg/kg and 200 mg/kg) has been evaluated for 
determining their antiulcer potential on ibuprofen, alcohol and pyloric ligation-induced gastric lesions using 
albino Wistar rats [63]. The results of this study showed that the methanolic extract reduced total gastric juice 
volume and free and total gastric secretion acidity in pylorus ligation-induced ulcer model, while reduced 
ulcer index (comparable with ranitidine, 50 mg/kg, as control) [186] 
Flavonoids Also known as bioflavonoids, some research suggested that these molecules may be beneficial in stomach 
ulcers, naturally present in many fruits and vegetables such as apple, soybeans, berries, and broccoli. As a 
disorder of the GI tract, pathological conditions in peptic ulcer could be alleviated by nutritional factors. 
Dietary consumption of a significant amount of “natural” protective supplements in early life leads to 
prevention or delayed peptic ulcer [187] 
Deglycyrrhizinated licorice It is beneficial in H. pylori‑associated ulcer. In modern medicine, licorice extract has been used for peptic ulcer 
and as an alternative to bismuth that has a protective role against acid and pepsin secretions by covering the 
site of lesion and promoting the mucous secretion [188]. 
Honey Natural honey is composed of around 82% carbohydrates, water, phytochemicals, proteins, minerals, and 
antioxidants. It is also beneficial in H. pylori‑associated ulcer because honey is a powerful antibacterial agent. 
In gastric curative effects of manuka honey in rat model with acetic acid-induced chronic gastric ulcer, manuka 
honey provided significant gastroprotective effects in acute gastric ulcer animal model [189] 
 
 
It has been shown that lactobacilli are particularly useful in promoting gastric ulcer healing in rats, when administered as an individual 
probiotic strain, such as Lactobacillus rhamnosus GG, Lactobacillus gasseri OLL2716, or Lactobacillus acidophilus or as a probiotic 
mixture, VSL#3. Lactobacillus rhamnosus GG increases the cellular proliferation to apoptosis ratio and therefore promotes 
regeneration of epithelial cells, particularly at the ulcer margins. In clinical studies, a probiotic mixture was demonstrated to be better 
than a single strain for improving the characteristics of indigenous microflora [191]. 
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Exhibit 11. Summary of studies on the therapeutic effects of probiotics in Gastric Ulcer [191] 
Probiotic strain(s) 
Modeling 
method Lesions Effects of probiotics 
Lactobacillus spp. Acetic acid Gastric ulcer Enhance healing of a pre-existing gastric ulcer 
Lactobacillus rhamnosus GG Acetic acid Gastric ulcer Inhibit cell apoptosis to proliferation ratio, and induce 
angiogenesis 
Lactobacillus gasseri OLL 2716 Acetic acid Gastric ulcer Accelerate healing by enhancing generation of gastric mucosal 
prostaglandin E2 
Lactobacillus acilidophilus encapsulated in 
ginger extract 
Stress Gastric ulcer Improve healing by restoring all biochemical, physiological and 
histological changes 
Lactobacillus acidophilus and alginate 
floating beads 
Stress Gastric ulcer Improve healing by restoring all biochemical, physiological and 
histological changes 
Probiotic mixture (VSL#3) (8 probiotic 
strains) 
Acetic acid Gastric ulcer Enhance healing by promoting angiogenesis via upregulation of 
vascular endothelial growth factor 
Saccharomyces boulardii Ibuprofen Gastric ulcer Potential treatment or prevention 
Polysaccharides fractions (PSFs) of 
Bifidobacterium breve and bifidum 
Acetic acid and 
ethanol 
Gastric erosion 
and ulcer 
Repair and protect gastric mucosa by increasing expression of 
epidermal and fibroblast growth factors and 6-ketoprostaglandin 
F1 
Probiotic mixture (2 bacterial strains) and 
composite probiotic (3 bacterial strains) 
Stress Gastric erosion 
and ulcer 
Reduce lesions and intensity of bleeding through the restoration 
of pro- and antioxidant balance 
Probiotic mixture (14 bacterial strains) Stress Gastric 
mucosal 
lesions 
Enhance recovery of stress hormones, downregulate pro-
inflammatory cytokines and upregulate anti-inflammatory 
cytokines 
 
Promising results for studies exploring both prophylactic and therapeutic effects (Exhibit 11) of probiotics have been obtained. The 
studies concerning the roles of probiotics in gastric ulcer healing reported in the literature were mainly conducted in rats. These 
studies were based on the use of either individual probiotic strains, such as Lactobacillus rhamnosus GG, Lactobacillus gasseri 
OLL2716, Lactobacillus acidophilus, Escherichia coli Nissle 1917, Bifidobacterium animalis VKL/VKB, Bifidobacterium bifidum/brevis 
and Saccharomyces boulardii, or a mixture of probiotic strains, such as VSL#3. A number of studies have reported that probiotics not 
only inhibit the development of acute gastric mucosal lesions, but also accelerate the process of healing of induced gastric ulcers 
[191].  
 
 
Figure 7. Mechanisms of action of probiotics. Probiotics are engaged to adherence to host epithelial tissue, acid resistance and bile tolerance, 
elimination    of   pathogens    or   reduction    in pathogenic adherence production of    acids, hydrogen peroxide and    bacteriocins   antagonistic   to    
pathogen growth, safety, non-pathogenic    and non-carcinogenic, and Improvement of intestinal microflora. Prebiotics of proven efficacy are able 
to modulate the gut microbiota by stimulating indigenous beneficial flora while inhibiting the growth of   pathogenic    bacteria    therein.    Preferred 
target organisms   for   prebiotics   are   specific. belonging to the Lactobacillus and Bifidobacterium genera. The most efficient prebiotics    may also 
reduce or    suppress numbers   and    activities   of   organisms   seen as   pathogenic (Bandyopadhyay B, Mandal NC. Probiotics, Prebiotics and 
Symbiotic - In Health Improvement by Modulating Gut Microbiota: The Concept Revisited. Int. J. Curr. Microbiol. App. Sci (2014) 3(3): 410-420)  
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Probiotics can also protect the integrity of the gastric mucosal barrier by upregulating prostaglandin, mucous secretion, tight junction 
protein expression and cell proliferation, and by inhibiting apoptosis (43,48,130–132). In rats, the administration of Bifidobacterium 
bifidum BF-1 or Bifidobacterium animalis VKL and VKB has been found to protect the gastric mucosa through either preventing the 
mucous barrier from degradation or increasing gastric mucous production. The probiotic mixture VSL#3 protects the epithelial barrier 
and upregulates the expression of tight junction proteins (occludin and zonula occludens-1) in vivo and in vitro via the activation of 
p38 or mitogen-activated protein (MAP) kinase and extracellular signal-regulated kinase (ERK) signaling pathways. Mennigen et al 
demonstrated that probiotics can strengthen the gastric mucosal barrier by inhibiting the redistribution and expression of tight 
junction proteins and blocking apoptosis (135). The probiotic strains Lactobacillus gasseri OLL2716, Lactobacillus rhamnosus GG and 
Escherichia coli Nissle 1917 are able to protect the altered gastric mucosal barrier (43,48,114). In humans, Gotteland et al found that 
pretreatment with Lactobacillus GG protected against indomethacin-induced disruption of the gastric mucosal barrier [191]. 
 
Exhibit 11. Selection criteria of probiotic strains [190] 
Criterion Required Properties 
Safety 
• Human or animal origin. 
• Isolated from the gastrointestinal tract of healthy individuals. 
• History of safe use. 
• Precise diagnostic identification (phenotype and genotype traits). 
• Absence of data regarding an association with infective disease. 
• Absence of the ability to cleave bile acid salts. 
• No adverse effects. 
• Absence of genes responsible for antibiotic resistance localized in non-stable elements. 
Functionality 
• Competitiveness with respect to the microbiota inhabiting the intestinal ecosystem. 
• Ability to survive and maintain the metabolic activity, and to grow in the target site. 
• Resistance to bile salts and enzymes. 
• Resistance to low pH in the stomach. 
• Competitiveness with respect to microbial species inhabiting the intestinal ecosystem (including closely related 
species). 
• Antagonistic activity towards pathogens (e.g., H. pylori, Salmonella sp., Listeria monocytogenes, Clostridium 
difficile). 
• Resistance to bacteriocins and acids produced by the endogenic intestinal microbiota. 
• Adherence and ability to colonise some particular sites within the host organism, and an appropriate survival rate 
in the gastrointestinal system. 
Technological 
usability 
• Easy production of high biomass amounts and high productivity of cultures. 
• Viability and stability of the desired properties of probiotic bacteria during the fixing process (freezing, freeze-
drying), preparation, and distribution of probiotic products. 
• High storage survival rate in finished products (in aerobic and micro-aerophilic conditions). 
• Guarantee of desired sensory properties of finished products (in the case of the food industry). 
• Genetic stability. 
• Resistance to bacteriophages. 
 
The mode of action of probiotics is not completely understood 
but they may act as surrogate normal microflora following 
antibiotic therapy until recovery is achieved. However, 
probiotic combinations appeared to induce only minor changes 
in the microbiota. For instance, the mechanisms of action of S. 
boulardii include luminal action (anti-toxic effect, antimicrobial 
activity), trophic action (enzymatic activity, increased IgA) and 
mucosal-anti-inflammatory signaling effects (decreased 
synthesis of inflammatory cytokines). Short-chain fatty acids 
(SCFAs) and bacteriocin proteins have been implicated in the 
inhibition of H. pylori by lactic acid bacteria. SCFAs such as 
formic, acetic, propionic, butyric and lactic acids are produced 
as a result of the metabolism of carbohydrates by probiotics 
and play an important role in decreasing the pH in vitro. Their 
antimicrobial activity could be due to the inhibition of urease 
activity by high lactic acid producers, such as Lactobacillus 
salivarius and Lactobacillus casei Shirota. Lactobacillus 
salivarius significantly decreased IL-8 production [IL-8 is 
induced after injection of virulence factor CagA into epithelial 
cells] upon exposure to H. pylori and led to CagA accumulation 
in H. pylori cells, presumably as a result of loss of functionality 
of the Cag secretion system. Alterations in gastrointestinal 
permeability are an initial step in the development of lesions 
such as ulcers. Probiotics may stabilize the intestinal barrier by 
stimulating the expression of gastric mucins, decreasing 
bacterial overgrowth and stimulating local immune responses 
and the release of antioxidant substances [192]. 
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Conclusion 
This review is conducted and correlate the published literature 
on the effectiveness of herbs and probiotics, for the treatment 
of FAPDs. Despite its common use, research on the efficacy, 
safety, and optimal dosage remains limited. Many responsible 
members of the dietary supplements industry have taken 
significant steps to regain consumer trust by improving 
transparency along the supply chain, enhancing traceability of 
raw botanical materials, and bringing attention to ingredients 
with potential adulteration concerns, among other efforts. 
Lifestyle and food habit also found important factor to improve 
GI related disorders to much extent. Several randomized 
controlled trials have now shown that microbial modification by 
probiotics may improve gastrointestinal symptoms and 
multiorgan inflammation in rheumatoid arthritis, ulcerative 
colitis, and multiple sclerosis. In the USA, microorganisms used 
for consumption purposes should have the GRAS status, 
regulated by the FDA. In Europe, EFSA introduced the term of 
QPS. The QPS concept involves some additional criteria of the 
safety assessment of bacterial supplements, including the 
history of safe usage and absence of the risk of acquired 
resistance to antibiotics. Future work will need to carefully 
assess safety issues, selection of optimal strains and 
combinations, and attempts to prolong the duration of 
colonization of beneficial microbes. This doesn't mean 
conventional therapies don't work, it just means that experts 
haven't studied them enough to know if they do. The most 
important thing is safe healing and better life. To ensure this, 
researchers needs to work more on both conventional and 
complimentary drugs. 
 
Abbreviations: The American College of Gastroenterology (ACG); 
Gastroesophageal Reflux Disease (GERD); Proton Pump Inhibitors 
(PPIs); Recurrent Abdominal Pain (RAP); Functional gastrointestinal 
disorders (FGIDs); Postprandial Distress Syndrome (PDS); 
Complementary and Alternative Medicine (CAM); Functional 
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